Sponsor

Clinical trials sponsored by AstraZeneca

Active studies whose public registry record names AstraZeneca as lead sponsor.

12active studies

6recruiting now

17countries represented

321largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

Obesity, OverweightCondition

Elecoglipron, PlaceboTreatment

China, Hong Kong49 locations

AstraZenecaSponsor

Updated 2026-08-27 · NCT07775404See eligibility →

Recruiting nowPhase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Obesity or OverweightCondition

AZD6234, PlaceboTreatment

Argentina, Australia212 locations

AstraZenecaSponsor

Updated 2026-08-25 · NCT07784725See eligibility →

Recruiting nowPhase 1

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

Healthy ParticipantsCondition

AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO)Treatment

United States2 locations

AstraZenecaSponsor

Updated 2026-08-18 · NCT07013643See eligibility →

Recruiting nowPhase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

Healthy Participants, ObesityCondition

AZD1043, PlaceboTreatment

United Kingdom, United States3 locations

AstraZenecaSponsor

Updated 2026-08-10 · NCT07511205See eligibility →

Recruiting nowPhase 3

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

Type 2 Diabetes MellitusCondition

Elecoglipron, SemaglutideTreatment

Argentina, Australia201 locations

AstraZenecaSponsor

Updated 2026-07-14 · NCT07662213See eligibility →

Recruiting nowPhase 3

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

Weight ManagementCondition

Elecoglipron, PlaceboTreatment

Argentina, Australia321 locations

AstraZenecaSponsor

Updated 2026-07-10 · NCT07667803See eligibility →

Opening soonPhase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Obesity or Overweight, Diabetes Mellitus, Type 2Condition

AZD6234, PlaceboTreatment

Argentina, Australia218 locations

AstraZenecaSponsor

Updated 2026-08-25 · NCT07784270See eligibility →

Opening soonPhase 3

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

Obesity or Overweight, Weight-Related ComorbidityCondition

AZD6234, PlaceboTreatment

Argentina, Brazil88 locations

AstraZenecaSponsor

Updated 2026-08-20 · NCT07776509See eligibility →

Active, not recruitingPhase 1, Phase 2

A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight

Overweight and ObesityCondition

AZD9550, placeboTreatment

Austria, Canada15 locations

AstraZenecaSponsor

Updated 2026-08-26 · NCT06151964See eligibility →

Active, not recruitingPhase 1

A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234

Healthy ParticipantsCondition

AZD6234 Formulation 1, AZD6234 Formulation 2 (low concentration)Treatment

United Kingdom1 locations

AstraZenecaSponsor

Updated 2026-08-13 · NCT07220954See eligibility →

Active, not recruitingPhase 2

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

Obesity/OverweightCondition

AZD6234, PlaceboTreatment

China3 locations

AstraZenecaSponsor

Updated 2026-07-02 · NCT07017179See eligibility →

Active, not recruitingPhase 2

Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

Endocrinology, Diabetes, Type IICondition

AZD6234, Placebo to matchTreatment

United States18 locations

AstraZenecaSponsor

Updated 2026-03-03 · NCT06851858See eligibility →

Related sponsors

Novo Nordisk A/S71 Eli Lilly and Company67 University of Colorado, Denver36 Cairo University31 Mayo Clinic29 Norwegian University of Science and Technology25

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.